JP2018514568A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514568A5 JP2018514568A5 JP2017556988A JP2017556988A JP2018514568A5 JP 2018514568 A5 JP2018514568 A5 JP 2018514568A5 JP 2017556988 A JP2017556988 A JP 2017556988A JP 2017556988 A JP2017556988 A JP 2017556988A JP 2018514568 A5 JP2018514568 A5 JP 2018514568A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- carbon atom
- fibrosis
- attached
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 6
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 4
- -1 methoxy, ethoxy Chemical group 0.000 claims description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 230000009787 cardiac fibrosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 description 6
- UXHIBYLONSGIOH-UHFFFAOYSA-N Cc1ccc(CCC(N2)=O)c2n1 Chemical compound Cc1ccc(CCC(N2)=O)c2n1 UXHIBYLONSGIOH-UHFFFAOYSA-N 0.000 description 1
- HBWCJMBLUCNJIS-UHFFFAOYSA-N Cc1nc(NCCC2)c2cc1 Chemical compound Cc1nc(NCCC2)c2cc1 HBWCJMBLUCNJIS-UHFFFAOYSA-N 0.000 description 1
- FSWRUYCICUXURT-UHFFFAOYSA-N Cc1nc(nccc2)c2cc1 Chemical compound Cc1nc(nccc2)c2cc1 FSWRUYCICUXURT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154894P | 2015-04-30 | 2015-04-30 | |
| US62/154,894 | 2015-04-30 | ||
| PCT/US2016/029962 WO2016176532A1 (en) | 2015-04-30 | 2016-04-29 | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018514568A JP2018514568A (ja) | 2018-06-07 |
| JP2018514568A5 true JP2018514568A5 (OSRAM) | 2019-05-30 |
Family
ID=56027176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556988A Withdrawn JP2018514568A (ja) | 2015-04-30 | 2016-04-29 | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9572801B2 (OSRAM) |
| EP (1) | EP3288555A1 (OSRAM) |
| JP (1) | JP2018514568A (OSRAM) |
| KR (1) | KR20170141757A (OSRAM) |
| CN (1) | CN108040467A (OSRAM) |
| AU (1) | AU2016255494A1 (OSRAM) |
| BR (1) | BR112017023432A2 (OSRAM) |
| CA (1) | CA2983312A1 (OSRAM) |
| IL (1) | IL255054A0 (OSRAM) |
| MX (1) | MX2017013880A (OSRAM) |
| RU (1) | RU2017141561A (OSRAM) |
| WO (1) | WO2016176532A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8901144B2 (en) * | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| US9518053B2 (en) | 2013-02-07 | 2016-12-13 | Scifluor Life Sciences, Inc. | Fluorinated integrin antagonists |
| EP3925959A1 (en) | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| US10118929B2 (en) | 2016-04-27 | 2018-11-06 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| BR112019017929A2 (pt) | 2017-02-28 | 2020-05-19 | Morphic Therapeutic Inc | inibidores de integrina (alfa-v)(beta-6) |
| EP4147698A1 (en) | 2017-02-28 | 2023-03-15 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| IL309955A (en) * | 2018-04-27 | 2024-03-01 | Arrowhead Pharmaceuticals Inc | Integrin-targeting ligands and their uses |
| TWI841573B (zh) * | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| ES3019404T3 (en) | 2018-08-29 | 2025-05-20 | Morphic Therapeutic Inc | Integrin inhibitors |
| WO2021225912A1 (en) * | 2020-05-07 | 2021-11-11 | Pliant Therapeutics, Inc. | Treatment of respiratory diseases with amino acid compounds |
| JP7585564B2 (ja) * | 2020-09-24 | 2024-11-19 | 株式会社ファンケル | セラミド含有ニオソームを含む化粧料 |
| WO2023231964A1 (zh) * | 2022-05-30 | 2023-12-07 | 赛诺哈勃药业（成都）有限公司 | 四氢萘啶衍生物在制备防治粘连相关疾病的药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1318254C (en) | 1988-01-06 | 1993-05-25 | Munehiro Tomikawa | Inhibitory agent of hepatic fibrosis containing pantethine |
| EP0581904B1 (en) | 1991-04-01 | 1997-05-28 | Duke University | Method of inhibiting fibrosis |
| JP3818322B2 (ja) | 1994-04-28 | 2006-09-06 | 敏一 中村 | コラーゲン分解促進剤 |
| US5645839A (en) | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
| US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| AU3215597A (en) | 1996-08-30 | 1998-03-19 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| CN1284955A (zh) * | 1997-12-17 | 2001-02-21 | 麦克公司 | 整联蛋白受体拮抗剂 |
| US6117445A (en) | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
| EP1192949A4 (en) | 2000-02-22 | 2005-11-09 | Daiichi Suntory Pharma Co Ltd | PREVENTIVE OR THERAPEUTIC DRUGS FOR TREATING FIBROSIS AND CONTAINING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS |
| AU2001292598B2 (en) | 2000-09-14 | 2006-06-29 | Merck & Co., Inc. | Alpha V integrin receptor antagonists |
| US6509347B2 (en) * | 2001-06-11 | 2003-01-21 | Merck & Co., Inc. | Crystalline forms of an integrin receptor antagonist |
| US9518053B2 (en) | 2013-02-07 | 2016-12-13 | Scifluor Life Sciences, Inc. | Fluorinated integrin antagonists |
| US8901144B2 (en) * | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| EP3925959A1 (en) * | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| US20180110762A1 (en) * | 2015-03-26 | 2018-04-26 | Merck Sharp & Dohme Corp | Compositions Methods for Treating Chronic Kidney Disease |
-
2016
- 2016-04-29 EP EP16724172.8A patent/EP3288555A1/en not_active Withdrawn
- 2016-04-29 BR BR112017023432A patent/BR112017023432A2/pt not_active Application Discontinuation
- 2016-04-29 KR KR1020177034091A patent/KR20170141757A/ko not_active Withdrawn
- 2016-04-29 US US15/142,023 patent/US9572801B2/en not_active Expired - Fee Related
- 2016-04-29 WO PCT/US2016/029962 patent/WO2016176532A1/en not_active Ceased
- 2016-04-29 CN CN201680036759.2A patent/CN108040467A/zh active Pending
- 2016-04-29 RU RU2017141561A patent/RU2017141561A/ru not_active Application Discontinuation
- 2016-04-29 CA CA2983312A patent/CA2983312A1/en not_active Abandoned
- 2016-04-29 MX MX2017013880A patent/MX2017013880A/es unknown
- 2016-04-29 AU AU2016255494A patent/AU2016255494A1/en not_active Abandoned
- 2016-04-29 JP JP2017556988A patent/JP2018514568A/ja not_active Withdrawn
-
2017
- 2017-10-16 IL IL255054A patent/IL255054A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514568A5 (OSRAM) | ||
| JP2019034943A5 (OSRAM) | ||
| JP2018510139A5 (OSRAM) | ||
| JP2016518328A5 (OSRAM) | ||
| JP2016518437A5 (OSRAM) | ||
| JP2016520618A5 (OSRAM) | ||
| JP2019094345A5 (OSRAM) | ||
| JP2017537940A5 (OSRAM) | ||
| JP2016040288A5 (OSRAM) | ||
| JP2016534063A5 (OSRAM) | ||
| JP2016509591A5 (OSRAM) | ||
| JP2017528503A5 (OSRAM) | ||
| RU2017141561A (ru) | Производные тетрагидронафтиридинилпропионовой кислоты и их применение | |
| JP2013544276A5 (OSRAM) | ||
| JP2016512547A5 (OSRAM) | ||
| JP2020507589A5 (OSRAM) | ||
| JP2016503797A5 (OSRAM) | ||
| JP2018537535A5 (OSRAM) | ||
| JP2017505779A5 (OSRAM) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2014500265A5 (OSRAM) | ||
| JP2017517538A5 (OSRAM) | ||
| JP2015521156A5 (OSRAM) | ||
| JP2019520344A5 (OSRAM) | ||
| JP2008546770A5 (OSRAM) |